The Importance of Molecular Profiling in Hematologic Diseases
Steven E. Coutre, MD, professor at the Stanford University Medical Center, discusses the importance of molecular profiling in hematologic diseases, including acute lymphoblastic leukemia.
Steven E. Coutre, MD, professor at the Stanford University Medical Center, discusses the importance of molecular profiling in hematologic diseases, including acute lymphoblastic leukemia (ALL).
Understanding the heterogeneity of a hematologic disease is an important part of making treatment decisions for patients. For example, the Philadelphia chromosome can help oncologists decide whether to put their patients with ALL on either dasatinib (Sprycel) or imatinib (Gleevec).
By having a more robust profile of patients, oncologists will have a better understanding of what drugs to give in combination with chemotherapy for the best outcome, Coutre explains.
